Efficacy and effects of Sotorasib

Sotorasib (Sotorasib) is an oral drug that targets the KRAS G12C mutation and is mainly used to treat advanced or metastatic non-small cell lung cancer (NSCLC) with this mutation. Sotoracib is a KRAS G12C inhibitor that specifically binds to mutated KRAS protein and blocks its activity. This mutation is one of the important drivers common in many cancers.

By inhibitingthe activity of the KRAS G12C mutation, sotoraxib interferes with the signaling pathways within cancer cells and reduces the proliferation and growth capabilities of tumor cells. Sotorasiib is approved for the treatment of patients with non-small cell lung cancer who have a KRAS G12C mutation, particularly those with advanced or metastatic NSCLC that is unresectable with surgery or radiation therapy. It offers a new treatment option that slows disease progression and improves patient survival. : Clinical trials have shown that sotoraxib can cause tumors to shrink or stop growing in some patients, and sustained therapeutic responses in some patients.

SotoracibThe original drug has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. The price of Hong Kong original research versionsotorasibuSpecifications120mg*240 tablets is about RMB 80,000, and the European original research version 120mg*240 tablets is priced at about RMB 44,040 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generic drugs for sale in other countries. The specifications of the Laos Element Pharmaceutical Factory are 120mg*56 tablets and the price is around 4800 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of foreign generic drugs are basically the same as the original drugs.